The Off Label Use of Glycopyrrolate in the Adults Intensive Care Unit.

• Status: Not yet recruiting
• Trial end date: 2021-04-10
• Target enrollment: 0
• Participant gender: All

Summary

Tracheostomized patients in the ICU can have excessive tracheal secretions due to various causes as hyperactive airway, irritation of the mucus producing cells and inhibition of the ciliary functions. Excessive secretions will necessitate frequent suctions which carries the risk of tracheostomy tube obstruction if not managed properly. Excessive tracheal secretions may prolong the ICU stay, increase the nurses workload and increase patients morbidity and mortality.

This clinical trial hypothesizes that the use of glycopyrrolate may decrease the tracheal secretions and hence avoid such complications.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Glycopyrrolate

Criteria

Inclusion Criteria:

1. Patients above 18 years old.

2. Patients who are admitted to ICU for more than 72 hours.

3. Patients who have tracheostomy tubes with reported frequent need for suction of the tracheostomy tube secretions more than once every 4 hours.

Exclusion Criteria:

1. Patients who have evidence of lower respiratory tract infections and have positive cultures from the tracheal aspirate.

2. Patients who have known sensitivity to Glycopyrrolate.

3. Patients who have tachycardia (heart rate above 120 Beats/minute) or known to have tachyarrhythmiase.g atrial fibrillation.

4. Patients with mitral stenosis